美国投行分析师看好奥布替尼治疗多发性硬化的差异化优势

同壁财经2025-12-17

美国投行H.C. Wainwright分析师Matthew Caufield 给予诺诚健华合作伙伴zenas biopharma “买入”评级，理由是Zenas正在研发BTK抑制剂奥布替尼在治疗进展型多发性硬化症 (PMS) 方面展现出良好的前景。Caufield认为，凭借独特的药代动力学特征和关键性试验设计，奥布替尼依然具有差异化优势。中枢神经系统透脑性更高以及和罗氏fenebrutinib...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2592998675?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2025-12-17 11:48","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2592998675","market":"hk","top_or_hot":-1,"title":"美国投行分析师看好奥布替尼治疗多发性硬化的差异化优势","media":"同壁财经","content":"<div>\n<p>美国投行H.C. Wainwright分析师Matthew Caufield 给予诺诚健华合作伙伴zenas biopharma “买入”评级，理由是Zenas正在研发BTK抑制剂奥布替尼在治疗进展型多发性硬化症 (PMS) 方面展现出良好的前景。Caufield认为 ，凭借独特的药代动力学特征和关键性试验设计，奥布替尼依然具有差异化优势。中枢神经系统透脑性更高以及和罗氏fenebrutinib...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251217115411a45516ab&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>美国投行分析师看好奥布替尼治疗多发性硬化的差异化优势</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n美国投行分析师看好奥布替尼治疗多发性硬化的差异化优势\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-12-17 11:48 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251217115411a45516ab&s=b><strong>同壁财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>美国投行H.C. Wainwright分析师Matthew Caufield 给予诺诚健华合作伙伴zenas biopharma “买入”评级，理由是Zenas正在研发BTK抑制剂奥布替尼在治疗进展型多发性硬化症 (PMS) 方面展现出良好的前景。Caufield认为 ，凭借独特的药代动力学特征和关键性试验设计，奥布替尼依然具有差异化优势。中枢神经系统透脑性更高以及和罗氏fenebrutinib...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251217115411a45516ab&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1574","symbol_name":"生物医药B类股","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251217115411a45516ab&s=b","article_id":"2592998675","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251217115411a45516ab&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2592998675","pubTimestamp":1765943331,"columns":[],"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"美国投行H.C. Wainwright分析师Matthew Caufield 给予诺诚健华合作伙伴zenas biopharma “买入”评级，理由是Zenas正在研发BTK抑制剂奥布替尼在治疗进展型多发性硬化症  方面展现出良好的前景。Caufield认为 ，凭借独特的药代动力学特征和关键性试验设计，奥布替尼依然具有差异化优势。此外，每天一次75毫克奥布替尼剂量组的疗效优于每天一次50毫克剂量组，这表明疗效呈剂量依赖性的改善趋势。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"BK1574":"生物医药B类股","BK1161":"生物科技","09969":"诺诚健华"},"translate_title":"U.S. investment bank analysts are optimistic about the differentiated advantages of orelabrutinib in the treatment of multiple sclerosis","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"09969":1.5},"content_text":"美国投行H.C. Wainwright分析师Matthew Caufield 给予诺诚健华合作伙伴zenas biopharma “买入”评级，理由是Zenas正在研发BTK抑制剂奥布替尼在治疗进展型多发性硬化症 (PMS) 方面展现出良好的前景。Caufield认为 ，凭借独特的药代动力学特征和关键性试验设计，奥布替尼依然具有差异化优势。中枢神经系统透脑性更高以及和罗氏fenebrutinib成功试验相一致的主要终点，进一步凸显了奥布替尼的差异化优势。此外，Caufield还强调，奥布替尼在治疗系统性红斑狼疮 (SLE) 的IIb期临床试验中的展示了积极的结果，这表明奥布替尼在多发性硬化以外的自免领域也具有广泛的市场前景。他指出，Zenas自身免疫研发和商业化平台潜力巨大，包括即将开展的其他候选药物的临床试验，增强了分析师 Caufield对Zenas的信心，因此重申买入评级和 44 美元的目标价。奥布替尼治疗SLE的临床IIb期结果展示，在接受治疗48周的患者中，奥布替尼展现了卓越的有效性和良好的耐受性和安全性。本次研究的主要终点是第48周时的SLE反应指数-4（SRI-4）应答率。第48周时，每天一次75毫克奥布替尼剂量组的SRI-4应答率显著高于安慰剂组（57.1% vs. 34.4%），具有统计学意义（p＜0.05），达到主要终点。此外，每天一次75毫克奥布替尼剂量组的疗效优于每天一次50毫克剂量组，这表明疗效呈剂量依赖性的改善趋势。亚组分析显示：在病情较重，活动度较高的亚组人群中，奥布替尼展现出更好的疗效。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2592998675","isCrawlerRequest":true}